• Publications
  • Influence
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
TLDR
Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo; there was no clinically significant difference between groups in the rates of serious adverse events and serious infections.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
TLDR
Moderate powered genome-wide association studies (GWAS) have enabled more than 20 additional risk loci to be identified and have shown that multiple variants exerting modest individual effects have a key role in disease susceptibility.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
TLDR
A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks and provides evidence of B-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis.
Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis
TLDR
Among patients with relapsing multiple sclerosis, ocrelizumab was associated with lower rates of disease activity and progression than interferon beta‐1a over a period of 96 weeks.
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial
Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci
TLDR
It is reported that the susceptibility allele near IRF8, which encodes a transcription factor known to function in type I Interferon signaling, is associated with higher mRNA expression of interferon-response pathway genes in subjects with MS.
Methods for high-density admixture mapping of disease genes.
Admixture mapping (also known as "mapping by admixture linkage disequilibrium," or MALD) has been proposed as an efficient approach to localizing disease-causing variants that differ in frequency
Interleukin 7 receptor α chain ( IL7R ) shows allelic and functional association with multiple sclerosis
TLDR
Allelic association of a polymorphism in the gene encoding the interleukin 7 receptor α chain ( IL7R) is described as a significant risk factor for multiple sclerosis in four independent family-based or case-control data sets.
Genome-wide patterns of population structure and admixture in West Africans and African Americans
Quantifying patterns of population structure in Africans and African Americans illuminates the history of human populations and is critical for undertaking medical genomic studies on a global scale.
...
1
2
3
4
5
...